摘要
为探讨SH对我国OA患者的疗效及耐受性,应用施沛特或Artz关节腔注射治疗膝OA患者133例共167个膝关节(施沛特组112膝,Artz组55膝)。施沛特组临床缓解率25.0％,总有效率93.8％,轻、中及重度患者有效率分别为100％、96.2％及83.3％;Artz组临床缓解率27.3％,总有效率96.4％,轻、中及重度患者有效率分别为100％、100％及81.8％。经统计学检验,两组无显著性差异(p>0.05)。二组治疗后各种症状均有明显改善,但以疼痛和肿胀改善最为显著;给药前三次(周),症状改善明显,后二次虽有改善,但程度小。患者对SH制剂耐受性好,未见有明显的毒、副反应。本文提示,施沛特治疗OA疗效确切、安全,同Artz相比较无显著性差异。
A study with two kinds of sodium hyaluronate preparations (Sofast and Artz) on 167 knees of 133 OA patients was conducted to evaluate their efficacy and tolerance. These drugs were administrated to the affected knee by intra-articular injection five times weekly. Twenty-eight (25%) knees in Sofast group (112 knees) were modified completely from the disease and 105 (93.8%) knees got improvement significantly in clinical signs versus 15(27.3%) knees and 53(96.4%) knees respectively in Artz group (55 knees). The improvement rates for knees with mild, moderate and severe signs were 100 % , 96.2 % and 83. 3 % in Sofast group versus 100 % , 100 % and 81. 8 % in Artz group respectively. There was no statistical significance in the difference between the two groups. No side effects and abnormal changes in the function of liver and kidney were found. The results indicate that Sofast as Artz is an effective and safe treatment for osteoarthritis of the knee.
